Immunitybio Azione

Immunitybio FCF/Debito

Rapporto Flusso di Cassa Libero / Debiti di Immunitybio (IBRX) al 19 ago 2026.

FCF/Debito

0,00

Ultimo aggiornamento:

Rapporto Flusso di Cassa Libero / Debiti di Immunitybio ammonta a 2026 0,00 . Rapporto Flusso di Cassa Libero / Debiti di Immunitybio ammontava a 2025 -53,26 % . Diminuisce del % superiore rispetto all'anno precedente.
Access this data via the Eulerpool API

Immunitybio Analisi delle Azioni

Cosa fa Immunitybio? Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Immunitybio azioni

Su Eulerpool è possibile consultare lo sviluppo storico completo del Immunitybio di Rapporto Flusso di Cassa Libero / Debiti dal 2006, con valori annuali, grafici e analisi dettagliate.

FCL/Debiti misura la percentuale del debito totale che potrebbe essere ripagata dal flusso di cassa libero. È una misura più rigorosa rispetto a FCO/Debiti in quanto tiene conto delle spese in conto capitale.

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare Immunitybio di Rapporto Flusso di Cassa Libero / Debiti con i competitor del settore e la media industriale per valutare se è attraente.

Access this data via the Eulerpool API

Leva finanziaria — Immunitybio

Tutte le Metriche Finanziarie — Immunitybio